Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim Illidge who told the Paris conference that tositumomab and ibritumomab tiuxetan have already proved effective. He explained to Peter Goodwin why he thinks the latest data look promising.
Sandra Horning
Abstract 349
Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine,
Reporting from:
American Society of Hematology Meeting, Atlanta, 10-13 December 2005
Scientific Editors:
George Canellos, Dana-Farber Cancer Institute, Boston
Gordon McVie, European Institute of
Post a comment